Who
Kevin Koch
President and CEO
Company insider
Files Form 4 as: President and CEO, Edgewise Therapeutics; Director, Viridian Therapeutics; President, CSO, Array Biopharma.
In numbers
- Trades disclosed
- 72
- Buys
- 0
- Sells
- 11
- Bought
- $0
- Sold
- $3.0M
- Companies
- 3
- Companies where not an officer
- 1
- First trade
- 17 Feb 2006
- Last trade
- 12 Aug 2026
- Last filed
- 14 Aug 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 12 Aug 2026filed 14 Aug 2026 | EWTX Edgewise TherapeuticsBiotechnology | SEC FORM 4 Code M | —17,969 at $0.00 | filing |
| 12 Aug 2026filed 14 Aug 2026 | EWTX Edgewise TherapeuticsBiotechnology | SEC FORM 4 Code M | —21,875 at $0.00 | filing |
| 12 Aug 2026filed 14 Aug 2026 | EWTX Edgewise TherapeuticsBiotechnology | SEC FORM 4 Sold | $383K8,782 at $43.64 | filing |
| 12 Aug 2026filed 14 Aug 2026 | EWTX Edgewise Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —17,969 at $0.00 | filing |
| 12 Aug 2026filed 14 Aug 2026 | EWTX Edgewise Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —21,875 at $0.00 | filing |
| 12 Aug 2026filed 14 Aug 2026 | EWTX Edgewise Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —100,000 at $0.00 | filing |
| 12 Aug 2026filed 14 Aug 2026 | EWTX Edgewise Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —200,000 at $0.00 | filing |
| 12 Aug 2026filed 14 Aug 2026 | EWTX Edgewise TherapeuticsBiotechnology | SEC FORM 4 Sold | $361K8,276 at $43.66 | filing |
| 12 Aug 2026filed 14 Aug 2026 | EWTX Edgewise TherapeuticsBiotechnology | SEC FORM 4 Sold | $40K913 at $44.33 | filing |
| 12 Aug 2026filed 14 Aug 2026 | EWTX Edgewise Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —17,969 at $0.00 | filing |
| 12 Aug 2026filed 14 Aug 2026 | EWTX Edgewise Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —21,875 at $0.00 | filing |
| 12 Aug 2026filed 14 Aug 2026 | EWTX Edgewise Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —100,000 at $0.00 | filing |
| 12 Aug 2026filed 14 Aug 2026 | EWTX Edgewise Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —200,000 at $0.00 | filing |
| 12 Aug 2026filed 14 Aug 2026 | EWTX Edgewise TherapeuticsBiotechnology | SEC FORM 4 Code M | —17,969 at $0.00 | filing |
| 12 Aug 2026filed 14 Aug 2026 | EWTX Edgewise TherapeuticsBiotechnology | SEC FORM 4 Code M | —21,875 at $0.00 | filing |
| 12 Aug 2026filed 14 Aug 2026 | EWTX Edgewise TherapeuticsBiotechnology | SEC FORM 4 Sold | $383K8,782 at $43.64 | filing |
| 12 Aug 2026filed 14 Aug 2026 | EWTX Edgewise TherapeuticsBiotechnology | SEC FORM 4 Sold | $361K8,276 at $43.66 | filing |
| 12 Aug 2026filed 14 Aug 2026 | EWTX Edgewise TherapeuticsBiotechnology | SEC FORM 4 Sold | $40K913 at $44.33 | filing |
| 12 Aug 2025filed 14 Aug 2025 | EWTX Edgewise Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —17,968 at $0.00 | filing |
| 12 Aug 2025filed 14 Aug 2025 | EWTX Edgewise Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —87,500 at $0.00 | filing |
News
No headline names them, or the companies they trade most, lately.